S&P・Nasdaq 本質的価値 お問い合わせ

ImmuCell Corporation ICCC NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/6 Pass
SharesGrow Intrinsic Value
$20.54
+170.3%

ImmuCell Corporation (ICCC) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Portland, ME, アメリカ. 現CEOは F. Olivier Te Boekhorst.

ICCC を有する IPO日 1987-05-05, 69 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $68.76M.

ImmuCell Corporation について

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

📍 56 Evergreen Drive, Portland, ME 04103 📞 207 878 2770
会社詳細
セクターヘルスケア
業種バイオテクノロジー
アメリカ
取引所NASDAQ Capital Marke
通貨USD
IPO日1987-05-05
CEOF. Olivier Te Boekhorst
従業員数69
取引情報
現在価格$7.60
時価総額$68.76M
52週レンジ4.52-7.6
ベータ0.31
ETFいいえ
ADRいいえ
CUSIP452525306
お問い合わせ
🎓
SharesGrow アカデミー
本質的価値の計算と割安株の見つけ方を学ぶ。
毎週のライブセッション
メッセージを送る